Treatment options in emerging mold infections

Current Infectious Disease Reports

Volumn 10, Issue 6, 2008, Pages 473-479

  Muñoz, Patricia ^a   Guinea, Jesús ^b   Bouza, Emilio ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; ALBACONAZOLE; AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; NATAMYCIN; PENTAMIDINE; POSACONAZOLE; PYRROLE DERIVATIVE; RIFAMPICIN; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS; CANDIDA; CLINICAL TRIAL; DEBRIDEMENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FUSARIOSIS; FUSARIUM; HUMAN; IMMUNOCOMPROMISED PATIENT; KERATITIS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR ECOLOGY; MOULD; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; NONHUMAN; REVIEW; SCEDOSPORIOSIS; SCEDOSPORIUM; SKIN INJURY; TISSUE NECROSIS; ZYGOMYCETES;

EID: 63249110025     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0077-9     Document Type: Review

References (50)

1. Nucci M, Marr KA, Queiroz-Telles F, et al.: Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38:1237-1242.
2. Singh J, Rimek D, Kappe R: In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 2005, 48:246-250.
3. Sabatelli F, Patel R, Mann PA, et al.: In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006, 50:2009-2015.
4. Eisen DP, Robson J: Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: More evidence of the utility of azoles for zygomycosis. Mycoses 2004, 47:159-162.
5. Dannaoui E, Meletiadis J, Mouton JW, et al.: In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003, 51:45-52.
6. Torres-Narbona M, Guinea J, Martinez-Alarcón J, et al.: In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 2007, 51:1126-1129.
7. Guembe M, Guinea J, Peláez T, et al.: Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother 2007, 51:3457-3458.
8. Guinea J, Peláez T, Recio S, et al.: In vitro antifungal activity of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008, 52:1396-1400.
9. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV: Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000, 30:851-856.
10. Prabhu RM, Patel R: Mucormycosis And entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004, 10(Suppl 1):31-47.
11. Gleissner B, Schilling A, Anagnostopolous I, et al.: Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004, 45:1351-1360.
12. Morduchowicz G, Shmueli D, Shapira Z, et al.: Rhinocerebral mucormycosis in renal transplant recipients: Report of three cases and review of the literature. Rev Infect Dis 1986, 8:441-446.
13. Trifilio S, Singhal S, Williams S, et al.: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451-456.
14. Oren I: Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005, 40:770-771.
15. Kontoyiannis DP, Lionakis MS, Lewis RE, et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
16. Vigouroux S, Morin O, Moreau P, et al.: Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005, 40:e35-e37.
17. Greenberg RN, Mullane K, van Burik JA, et al.: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
18. van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65.
19. Rickerts V, Atta J, Herrmann S, et al.: Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses 2006, 49(Suppl 1):27-30.
20. John BV, Chamilos G, Kontoyiannis DP: Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005, 11:515-517.
21. Nelson PE, Dignani MC, Anaissie EJ: Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994, 7:479-504.
22. Anaissie EJ, Kuchar RT, Rex JH, et al.: Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: A new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001, 33:1871-1878.
23. Nucci M, Anaissie E: Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007, 20:695-704.
24. Espinel-Ingroff A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003, 20:121-136.
25. García-Effrón G, Gómez-López A, Mellado E, et al.: In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 2004, 53:1086-1089.
26. Rao SK, Lam PT, Li EY, et al.: A case series of contact lensassociated Fusarium keratitis in Hong Kong. Cornea 2007, 26:1205-1209.
27. Nucci M, Anaissie EJ, Queiroz-Telles F, et al.: Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003, 98:315-319.
28. Perfect JR: Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005, 40(Suppl 6):S401-S408.
29. Perfect JR, Marr KA, Walsh TJ, et al.: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
30. Raad II, Hachem RY, Herbrecht R, et al.: Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42:1398-1403.
31. Husain S, Muñoz P, Forrest G, et al.: Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: Clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005, 40:89-99.
32. Revankar SG, Patterson JE, Sutton DA, et al.: Disseminated phaeohyphomycosis: Review of an emerging mycosis. Clin Infect Dis 2002, 34:467-476.
33. Berenguer J, Rodríiguez-Tudela JL, Richard C, et al.: Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) 1997, 76:256-265.
34. Guerrero A, Torres P, Durán MT, et al.: Airborne outbreak of nosocomial Scedosporium prolificans infection. Lancet 2001, 357:1267-1268.
35. Husain S, Alexander BD, Muñoz P, et al.: Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003, 37:221-229.
36. Ruchel R, Wilichowski E: Cerebral Pseudallescheria mycosis after near-drowning. Mycoses 1995, 38:473-475.
37. Safdar A, Papadopoulos EB, Young JW: Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiosis and recent advances in antifungal therapy. Transpl Infect Dis 2002, 4:212-217.
38. Espinel-Ingroff A, Johnson E, Hockey H, Troke P: Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J Antimicrob Chemother 2008, 61:616-620.
39. Cortez KJ, Roilides E, Quiroz-Telles F, et al.: Infections caused by Scedosporium spp. Clin Microbiol Rev 2008, 21:157-197.
40. Carrillo AJ, Guarro J: In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001, 45:2151-2153.
41. Meletiadis J, Meis JF, Mouton JW, et al.: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002, 46:62-68.
42. Meletiadis J, Mouton JW, Meis JF, Verweij PE: In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003, 47:106-117.
43. Afeltra J, Dannaoui E, Meis JF, et al.: In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother 2002, 46:3323-3326.
44. Heyn K, Tredup A, Salvenmoser S, Muller FM: Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005, 49:5157-5159.
45. Reimann D, Bussemaker E, Gross P: Successful treatment due to vacuum seal technique of a severe Scedosporium apiospermum skin infection in a renal transplant recipient. Nephrol Dial Transplant 2004, 19:245-248.
46. Muñoz P, Singh N, Bouza E: Treatment of solid organ transplant patients with invasive fungal infections: Should a combination of antifungal drugs be used? Curr Opin Infect Dis 2006, 19:365-370.
47. Barbaric D, Shaw PJ: Scedosporium infection in immunocompromised patients: Successful use of liposomal amphotericin B and itraconazole. Med Pediatr Oncol 2001, 37:122-125.
48. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ: Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002, 34:1648-1650.
49. Gil-Lamaignere C, Roilides E, Mosquera J, et al.: Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002, 46:2234-2237.
50. Ortoneda M, Capilla J, Pujol I, et al.: Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother 2002, 49:525-529.